Last Modified: October 8, 2004
Conference Dates: December 4, 2004
Conference Location: Chicago, IL
Conference Web Page URL: www.thecbce.com/futureprograms.asp
Topics Covered: Overview of EGFR Small-Molecule TKIs, Update on Recent Clinical Data for Small-Molecule TKIs, Second-Line Options for the Treatment of NSCLC, Clinical Variables of Patient Benefit: Who Should We Be Treating?, EGFR Small-Molecule TKIs and Rash: What Does it Mean?, Somatic Mutations and Response to EGFR Small-Molecule TKIs, Case Studies
Who Should Attend: This activity is designed primarily for medical oncologists and other healthcare professionals interested in the treatment of cancer.
Continuing Education: Yes
Apr 9, 2014 - For patients with non-small-cell lung cancer and wild-type epidermal growth factor receptor (EGFR) mutations, conventional chemotherapy improves progression-free survival better than first-generation EGFR tyrosine kinase inhibitors, according to research published in the April 9 issue of the Journal of the American Medical Association.
Jul 29, 2011
Jun 24, 2010